Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2013-10-17 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is explicitly titled 'Voting Rights Announcements' and details a notification from Mr. Mark N. Lampert regarding the exceedance of a voting rights threshold (10%) pursuant to German securities law (WpHG). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or related announcements concerning voting rights thresholds.
2013-10-17 English
Declaration of Voting Results & Voting Rights Announcements 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states it is a 'Release according to Article 26, Section 1 of the WpHG' concerning BVF Inc. informing Evotec AG about exceeding a voting rights threshold. This directly corresponds to the definition of a Voting Rights Announcement. Although the content details the reporting person's intentions regarding voting rights, the primary classification based on the header and content theme is related to voting rights disclosure. This aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a notification about voting rights status, even if it's not the final result of a vote, but rather a threshold crossing notification which falls under this umbrella in many regulatory contexts. It is not a general regulatory filing (RNS) because a more specific category exists.
2013-10-17 English
Declaration of Voting Results & Voting Rights Announcements 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states 'Voting Rights Announcements' in the header and details the notification from BVF Partners L.P. regarding the exceedance of a voting rights threshold, referencing Article 26, Section 1 of the WpHG. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The filing code for this is DVA.
2013-10-17 English
Evotec to hold R&D Day 2013
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 16, 2013, announcing that Evotec AG will hold an 'R&D Day 2013' on October 22, 2013. It details the date, venue, presenters, and the topics to be covered (drug discovery infrastructures, core disease areas, regenerative medicine). This is an announcement about a future investor/research event, not the presentation material itself, nor is it a standard regulatory filing like a 10-K or an earnings release. Since it is an announcement about an event where presentations will be given, it most closely aligns with an Investor Presentation (IP) announcement or, given the nature of the announcement itself, it could be classified as a general Regulatory Filing (RNS) if a more specific category doesn't fit. However, since the content is entirely focused on informing investors/the public about an upcoming presentation/event where detailed information will be shared, it is best classified as an announcement related to investor communication. Given the options, and noting that it is not a formal report but an announcement of an event where an investor presentation will occur, RNS (Regulatory Filings/General Announcement) is the safest fallback, although 'IP' might be considered if the announcement itself was the presentation. Since this is an announcement *of* the event, and not the presentation material or a standard financial report, RNS is appropriate as a general corporate news item distributed via DGAP.
2013-10-16 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a financial research report prepared by an external third-party firm, Close Brothers Seydler Research AG, regarding Evotec AG. It includes investment recommendations (BUY), price targets, financial projections, and detailed analysis of company performance. This type of document is classified as an Investor Presentation or Research Report, which falls under the 'Regulatory Filings' (RNS) category in this schema as it is a third-party analysis rather than a primary company filing like a 10-K or Interim Report. 9M 2013
2013-10-16 English
Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim
Regulatory Filings Classification · 99% confidence The document is a short press release dated October 15, 2013, announcing that Evotec AG achieved a pre-clinical milestone in its discovery alliance with Boehringer Ingelheim, triggering a revenue payment of EUR 4.0 million. This type of announcement, detailing a specific business development (alliance progress, milestone payment) but not comprehensive financial results (like a 10-K or ER), typically falls under general corporate news or regulatory announcements. Since it is not a formal financial report (10-K, IR, ER, MRQ) and specifically details a partnership event, it is best classified as a general Regulatory Filing (RNS) as it is disseminated via DGAP, which handles 'Regulatory Announcements, Financial/Corporate News and Press Releases.' It does not fit the specific criteria for M&A (TAR), Capital changes (CAP/SHA), or Director dealings (DIRS). Given the nature of the announcement (a corporate update disseminated via a regulatory service), RNS is the most appropriate general category.
2013-10-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.